Edwards Lifesciences Corporation (NYSE:EW) had its target price raised by Barclays PLC from $108.00 to $120.00 in a report issued on Thursday. The brokerage currently has an equal weight rating on the medical research company’s stock.

A number of other research firms have also commented on EW. Jefferies Group LLC lifted their price objective on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a buy rating in a research note on Thursday. Bank of America Corporation lifted their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a buy rating in a research note on Thursday. BidaskClub lowered Edwards Lifesciences Corporation from a strong-buy rating to a buy rating in a research note on Wednesday, July 19th. Stifel Nicolaus reiterated a buy rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday. Finally, Zacks Investment Research lowered Edwards Lifesciences Corporation from a strong-buy rating to a hold rating in a research note on Monday, July 17th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $121.13.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded down 0.68% on Thursday, reaching $114.73. The company had a trading volume of 615,245 shares. The firm has a market capitalization of $24.15 billion, a PE ratio of 34.80 and a beta of 0.63. The company has a 50-day moving average price of $117.23 and a 200-day moving average price of $104.08. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. During the same period last year, the company earned $0.76 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Corporation will post $3.53 EPS for the current fiscal year.

WARNING: “Edwards Lifesciences Corporation (NYSE:EW) Price Target Raised to $120.00” was first published by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/edwards-lifesciences-corporation-nyseew-price-target-raised-to-120-00/1464096.html.

In other news, VP Donald E. Bobo, Jr. sold 34,120 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $109.98, for a total value of $3,752,517.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of the business’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $109.71, for a total value of $5,386,761.00. The disclosure for this sale can be found here. Insiders sold a total of 184,951 shares of company stock worth $20,780,242 over the last three months. 2.13% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Korea Investment CORP increased its position in shares of Edwards Lifesciences Corporation by 238.2% in the second quarter. Korea Investment CORP now owns 145,483 shares of the medical research company’s stock valued at $17,202,000 after buying an additional 102,467 shares during the last quarter. Egerton Capital UK LLP acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter valued at approximately $217,805,000. Lockheed Martin Investment Management Co. increased its position in shares of Edwards Lifesciences Corporation by 86.7% in the second quarter. Lockheed Martin Investment Management Co. now owns 23,900 shares of the medical research company’s stock valued at $2,826,000 after buying an additional 11,100 shares during the last quarter. Johnston Asset Management LLC boosted its position in Edwards Lifesciences Corporation by 12.1% in the second quarter. Johnston Asset Management LLC now owns 379,351 shares of the medical research company’s stock valued at $44,854,000 after buying an additional 40,850 shares during the period. Finally, CAPROCK Group Inc. bought a new position in Edwards Lifesciences Corporation during the second quarter valued at $318,000. 83.80% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.